<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819377</url>
  </required_header>
  <id_info>
    <org_study_id>08-1004</org_study_id>
    <nct_id>NCT00819377</nct_id>
  </id_info>
  <brief_title>Milrinone Inhaled in Cardiac Surgery</brief_title>
  <official_title>2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andre Denault</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and stoke fondation of Quebec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Organon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Anesthesiologists' Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary hypertension is an important morbidity factor in patients having to undergo cardiac
      surgery with cardiopulmonary bypass (ECC). Milrinone used in inhalation, shows evidence of
      being a pulmonary vasodilator able to possibly contribute to the reduction of pressure on the
      pulmonary artery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This controlled, randomized, double-blind study will aim at confirming the efficiency as well
      as the security of Milrinone, used in inhalation, to diminish the degree of pulmonary
      hypertension before the cardiopulmonary bypass (ECC) circulation. In addition, the
      pharmacokinetic and echo graphic repercussions of administering the medication will be
      analysed. At the present time, there is no data on the pharmacokinetics of the medication
      when it's administered through inhalation. For this reason, we would like to study the serous
      rate of the medication in the minutes following its administration through inhalation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate that inhaled milrinone administered before CPB is superior to placebo in reducing the severity of difficult separation from bypass</measure>
    <time_frame>End of CPB</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in morbidity and mortality post-op</measure>
    <time_frame>At discharge, 3 months, 6 months and 1 year by telephone</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in pulmonary artery pressure</measure>
    <time_frame>Same day before and after CPB</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular function measured using transthoracic echocardiography (TTE) and TEE</measure>
    <time_frame>Same day before and after the CPB</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of milrinone in relation with the pharmacodynamic marker</measure>
    <time_frame>Same day pre CPB per CPB and post CPB</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reduction of the composite index of hemodynamic complications (defined as hospital death, vasoactive drugs &gt; 24 hours and post-op cardiac arrest),</measure>
    <time_frame>24 hrs post op and hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Valvular Stenosis</condition>
  <condition>Valvular Insufficiency</condition>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline by inhalation over 15 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milrinone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled milrinone 5 mg(as for the injectable solution)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone</intervention_name>
    <description>inhaled milrinone 5 mg (as for the injectable solution)</description>
    <arm_group_label>Milrinone</arm_group_label>
    <other_name>Milrinone Cardiac Surgery</other_name>
    <other_name>Milrinone inhaled</other_name>
    <other_name>Inhaled milrinone reduces pulmonary artery pressure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>5 ml normal saline by inhalation over 15 min</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients scheduled for elective valvular or complex (2 or more valves or

          -  valve and revascularization) cardiac surgery under CPB with preoperative PHT defined
             as mean pulmonary artery pressure (MPAP) over 30 mmHg or

          -  systolic pulmonary artery pressure (SPAP) over 40 mmHg (using preoperative right-sided
             catheterization or estimated by echocardiography).

        Exclusion Criteria:

          -  Cardiac surgery not requiring CPB, contraindication to TEE (esophageal pathology or
             unstable cervical spine) and emergency surgery.

          -  Patients will be recruited the day before surgery and randomized using computerized
             cards by the pharmacy department
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denault Andr√©, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Baim DS, McDowell AV, Cherniles J, Monrad ES, Parker JA, Edelson J, Braunwald E, Grossman W. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure. N Engl J Med. 1983 Sep 29;309(13):748-56.</citation>
    <PMID>6888453</PMID>
  </reference>
  <reference>
    <citation>Denault AY, Lamarche Y, Couture P, Haddad F, Lambert J, Tardif JC, Perrault LP. Inhaled milrinone: a new alternative in cardiac surgery? Semin Cardiothorac Vasc Anesth. 2006 Dec;10(4):346-60. Review.</citation>
    <PMID>17200091</PMID>
  </reference>
  <reference>
    <citation>Omae T, Kakihana Y, Mastunaga A, Tsuneyoshi I, Kawasaki K, Kanmura Y, Sakata R. Hemodynamic changes during off-pump coronary artery bypass anastomosis in patients with coexisting mitral regurgitation: improvement with milrinone. Anesth Analg. 2005 Jul;101(1):2-8, table of contents.</citation>
    <PMID>15976197</PMID>
  </reference>
  <reference>
    <citation>Kikura M, Levy JH, Michelsen LG, Shanewise JS, Bailey JM, Sadel SM, Szlam F. The effect of milrinone on hemodynamics and left ventricular function after emergence from cardiopulmonary bypass. Anesth Analg. 1997 Jul;85(1):16-22.</citation>
    <PMID>9212116</PMID>
  </reference>
  <reference>
    <citation>Lobato EB, Florete O Jr, Bingham HL. A single dose of milrinone facilitates separation from cardiopulmonary bypass in patients with pre-existing left ventricular dysfunction. Br J Anaesth. 1998 Nov;81(5):782-4.</citation>
    <PMID>10193294</PMID>
  </reference>
  <reference>
    <citation>Iwagaki T, Irie J, Ijichi K, Uratsuji Y. [The effects of milrinone on hemodynamics in patients undergoing cardiac surgery]. Masui. 2001 Apr;50(4):360-4. Japanese.</citation>
    <PMID>11345746</PMID>
  </reference>
  <reference>
    <citation>Shibata T, Suehiro S, Sasaki Y, Hosono M, Nishi S, Kinoshita H. Slow induction of milrinone after coronary artery bypass grafting. Ann Thorac Cardiovasc Surg. 2001 Feb;7(1):23-7.</citation>
    <PMID>11343562</PMID>
  </reference>
  <reference>
    <citation>Kim JH, Ham BM, Kim YL, Bahk JH, Ryu HG, Jeon YS, Kim KB. Prophylactic milrinone during OPCAB of posterior vessels: implication in angina patients taking beta-blockers. Eur J Cardiothorac Surg. 2003 Nov;24(5):770-6.</citation>
    <PMID>14583311</PMID>
  </reference>
  <reference>
    <citation>Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, Bailey JM, Akbary A, Kocsis JF, Kaczmarek R, Spray TL, Wessel DL. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003 Feb 25;107(7):996-1002.</citation>
    <PMID>12600913</PMID>
  </reference>
  <reference>
    <citation>Maslow AD, Regan MM, Schwartz C, Bert A, Singh A. Inotropes improve right heart function in patients undergoing aortic valve replacement for aortic stenosis. Anesth Analg. 2004 Apr;98(4):891-902, table of contents.</citation>
    <PMID>15041568</PMID>
  </reference>
  <reference>
    <citation>Doolan LA, Jones EF, Kalman J, Buxton BF, Tonkin AM. A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1997 Feb;11(1):37-41.</citation>
    <PMID>9058218</PMID>
  </reference>
  <reference>
    <citation>Yamada T, Takeda J, Katori N, Tsuzaki K, Ochiai R. Hemodynamic effects of milrinone during weaning from cardiopulmonary bypass: comparison of patients with a low and high prebypass cardiac index. J Cardiothorac Vasc Anesth. 2000 Aug;14(4):367-73.</citation>
    <PMID>10972598</PMID>
  </reference>
  <reference>
    <citation>Solina A, Papp D, Ginsberg S, Krause T, Grubb W, Scholz P, Pena LL, Cody R. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth. 2000 Feb;14(1):12-7.</citation>
    <PMID>10698385</PMID>
  </reference>
  <reference>
    <citation>Denault AY, Chaput M, Couture P, H√©bert Y, Haddad F, Tardif JC. Dynamic right ventricular outflow tract obstruction in cardiac surgery. J Thorac Cardiovasc Surg. 2006 Jul;132(1):43-9.</citation>
    <PMID>16798301</PMID>
  </reference>
  <reference>
    <citation>Couture P, Denault AY, Pellerin M, Tardif JC. Milrinone enhances systolic, but not diastolic function during coronary artery bypass grafting surgery. Can J Anaesth. 2007 Jul;54(7):509-22.</citation>
    <PMID>17602036</PMID>
  </reference>
  <reference>
    <citation>Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991 Nov 21;325(21):1468-75.</citation>
    <PMID>1944425</PMID>
  </reference>
  <reference>
    <citation>Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002 Mar 27;287(12):1541-7.</citation>
    <PMID>11911756</PMID>
  </reference>
  <reference>
    <citation>Lamarche Y, Malo O, Thorin E, Denault A, Carrier M, Roy J, Perrault LP. Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005 Jul;130(1):83-92.</citation>
    <PMID>15999045</PMID>
  </reference>
  <reference>
    <citation>Haraldsson s A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg. 2001 Dec;93(6):1439-45, table of contents.</citation>
    <PMID>11726420</PMID>
  </reference>
  <reference>
    <citation>Sablotzki A, Starzmann W, Scheubel R, Grond S, Czeslick EG. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can J Anaesth. 2005 Dec;52(10):1076-82.</citation>
    <PMID>16326679</PMID>
  </reference>
  <reference>
    <citation>Bernstein AD, Parsonnet V. Bedside estimation of risk as an aid for decision-making in cardiac surgery. Ann Thorac Surg. 2000 Mar;69(3):823-8.</citation>
    <PMID>10750767</PMID>
  </reference>
  <reference>
    <citation>Lamarche Y, Perrault LP, Maltais S, T√©treault K, Lambert J, Denault AY. Preliminary experience with inhaled milrinone in cardiac surgery. Eur J Cardiothorac Surg. 2007 Jun;31(6):1081-7. Epub 2007 Apr 2.</citation>
    <PMID>17400468</PMID>
  </reference>
  <reference>
    <citation>Robitaille A, Denault AY, Couture P, B√©lisle S, Fortier A, Guertin MC, Carrier M, Martineau R. Importance of relative pulmonary hypertension in cardiac surgery: the mean systemic-to-pulmonary artery pressure ratio. J Cardiothorac Vasc Anesth. 2006 Jun;20(3):331-9. Epub 2006 Apr 19.</citation>
    <PMID>16750732</PMID>
  </reference>
  <reference>
    <citation>Lindsay CA, Barton P, Lawless S, Kitchen L, Zorka A, Garcia J, Kouatli A, Giroir B. Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr. 1998 Feb;132(2):329-34.</citation>
    <PMID>9506650</PMID>
  </reference>
  <reference>
    <citation>Oddie CJ, Jackman GP, Bobik A. Analysis of milrinone in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr. 1986 Jan 10;374(1):209-14.</citation>
    <PMID>3949932</PMID>
  </reference>
  <reference>
    <citation>Hudson RJ, Thomson IR, Jassal R. Effects of cardiopulmonary bypass on sufentanil pharmacokinetics in patients undergoing coronary artery bypass surgery. Anesthesiology. 2004 Oct;101(4):862-71.</citation>
    <PMID>15448518</PMID>
  </reference>
  <reference>
    <citation>Fiset P, Mathers L, Engstrom R, Fitzgerald D, Brand SC, Hsu F, Shafer SL. Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. Anesthesiology. 1995 Nov;83(5):944-55.</citation>
    <PMID>7486179</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <last_update_submitted>October 23, 2013</last_update_submitted>
  <last_update_submitted_qc>October 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Montreal Heart Institute</investigator_affiliation>
    <investigator_full_name>Andre Denault</investigator_full_name>
    <investigator_title>MD FRCPC ABIM-CCM</investigator_title>
  </responsible_party>
  <keyword>Valvular surgery</keyword>
  <keyword>pulmonary artery pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milrinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

